betrixaban

Even after Portola Pharmaceuticals Inc (NASDAQ: PTLA) shares soared nearly 50 percent following news of betrixaban receiving FDA approval (reported on Benzinga Pro), Oppenheimer analyst Jay Olson sees further upside. Olson maintains an Outperform rating on Portola with a $66 price target. A Closer...

The hot biotech space is set to witness a month of brimming activity in June, as several prospective treatment candidates are up on the altar to receive the blessings of the FDA. Two new molecular entities were approved in May, taking the tally for this year to 20. How The Sector Has Fared Thus...

Morgan Stanley is bullish on Portola Pharmaceuticals Inc (NASDAQ: PTLA) following the FDA acceptance of betrixaban for priority review. With priority review, betrixaban will receive an accelerated assessment of six months with a PDUFA date of June 24, 2017. Betrixaban is an oral, once-daily Factor...

Portola Pharmaceuticals Inc (NASDAQ: PTLA) announced the FDA acceptance of the new drug application and European Medicines Agency validation of the marketing authorization for betrixaban for use in acute medically ill patients. With this news, the application’s probability of success has...

Morgan Stanley’s Matthew Harrison believes regulatory updates regarding AndexXa and betrixaban were key drivers for Portola Pharmaceuticals Inc (NASDAQ: PTLA), which could offer clarity regarding approval timelines and restore investor confidence. Harrison maintains an Overweight rating on...

Credit Suisse has downgraded Portola Pharmaceuticals Inc (NASDAQ: PTLA) to Neutral from Outperform on balanced risk/reward following the recovery in shares since late March. The brokerage also cut its price target by $3 to $30 on "more conservative assumptions around the uptake of Andexanet Alfa...